… ;2a clinical trial in Q2 2024. Additionally, we announced … Life, a not-for-profit spinal cord injury research … Kelly brings three decades of pharmaceutical experience, playing instrumental roles … limitation, a lack of revenue, insufficient funding, the impact …

… dividend for the second quarter of 2024 of … profits through small and mid-cap biotechnology companies to leading global pharmaceutical … companies. Royalty Pharma has assembled … leading therapies. Royalty Pharma funds innovation in …

… dividend for the second quarter of 2024 of … profits through small and mid-cap biotechnology companies to leading global pharmaceutical … companies. Royalty Pharma has assembled … leading therapies. Royalty Pharma funds innovation in …

… COVID-19 testing-related revenue compared to the previous … growth came from Established Pharmaceuticals (up 13.7% organic … Medical Devices and Established Pharmaceuticals.” Abbott’s adjusted diluted … 4.62. Abbott projects second-quarter adjusted EPS Of $1. …

Join our daily newsletter At The Bell to receive exclusive market insights Little Green Pharma (ASX:LGP) wound up Q1CY24 with $5M in cash after posting record cash receipts of $8.1M, up 53% QoQ. On a year-on-year basis, cash receipts were up 21% “driven by …

… for delivery in the Q2 FY24, providing considerable potential … , Endoca, Quantum. MedTEC Pharma has also chosen HHA as … delivered $647,000 in revenue during the quarter, reflecting … diligently towards growing our substantial revenue base.”   This article …

Let’s be real – the narrative for Dow stocks to buy now tends to be one of relative safety. What are the chances that the 30 companies of the Dow Jones Industrial Average will be the most exciting ideas of any given year? I’d say quite low. However, …

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) reported its financial results for the fourth quarter and full year ending December 31, 2023, after the market closed on Monday.  Revenue fell 21% to $ 21 million for the fourth quarter versus 2022’s revenue …

After markets closed on Friday, April 12,  Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) announced its financial results for the second quarter ending February 29, 2024. Revenues declined sequentially by 15.4% from the prior quarter to $5 million in the …

… first quarter since 2016. Revenue for the three months … quarter forecast: Abbott expects second-quarter earnings to fall to … nutrition, diagnostics, and established pharmaceuticals — though the misses were … NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED. An Abbott …